We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
The FDA gave Conor Medsystems conditional approval of an investigational device exemption (IDE) last week to begin its COSTAR II pivotal clinical trial to support U.S. regulatory approval of the company’s CoStar stent.